Association between CD8+ T-cell infiltration and breast

Annals of Oncology

25, 1536-1543

Citation Report

#	Article	IF	Citations
2	Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2014, 148, 525-534.	1.1	84
3	The immunogenicity of breast cancerâ€"molecular subtypes matter. Annals of Oncology, 2014, 25, 1453-1455.	0.6	29
4	The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Breast Cancer Research and Treatment, 2014, 148, 467-476.	1.1	205
5	Emerging roles of regulatory T cells in tumour progression and metastasis. Cancer and Metastasis Reviews, 2014, 33, 1025-1041.	2.7	54
6	Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Research, 2015, 17, 124.	2.2	210
7	Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget, 2015, 6, 5449-5464.	0.8	424
8	The Prognostic Value of Forkhead Box P3 Expression in Operable Breast Cancer: A Large-Scale Meta-Analysis. PLoS ONE, 2015, 10, e0136374.	1.1	15
9	<i>PDL1</i> expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget, 2015, 6, 13506-13519.	0.8	105
10	Whole-transcriptome analysis of flow-sorted cervical cancer samples reveals that B cell expressed TCL1A is correlated with improved survival. Oncotarget, 2015, 6, 38681-38694.	0.8	15
11	Pathwayâ€based personalized analysis of breast cancer expression data. Molecular Oncology, 2015, 9, 1471-1483.	2.1	38
12	PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes. Annals of Oncology, 2015, 26, 1488-1493.	0.6	234
13	Prognostic and predictive immune gene signatures in breast cancer. Current Opinion in Oncology, 2015, 27, 433-444.	1.1	75
14	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. EBioMedicine, 2015, 2, 681-689.	2.7	56
15	Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2015, 7, 232-241.	0.5	0
16	Survivorship in untreated breast cancer patients. Medical Oncology, 2015, 32, 466.	1.2	6
17	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1
18	Prediagnostic serum inflammatory markers in relation to breast cancer risk, severity at diagnosis and survival in breast cancer patients. Carcinogenesis, 2015, 36, 1121-1128.	1.3	43
19	Intravital and Whole-Organ Imaging Reveals Capture of Melanoma-Derived Antigen by Lymph Node Subcapsular Macrophages Leading to Widespread Deposition on Follicular Dendritic Cells. Frontiers in Immunology, 2015, 6, 114.	2.2	36

#	Article	IF	Citations
20	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	2.3	177
21	Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type *TP53*. Molecular Cancer Research, 2015, 13, 493-501.	1.5	53
22	Breast Cancer Update 2014 â€" Focus on the Patient and the Tumour. Geburtshilfe Und Frauenheilkunde, 2015, 75, 170-182.	0.8	9
23	Natural and therapy-induced immunosurveillance in breast cancer. Nature Medicine, 2015, 21, 1128-1138.	15.2	268
24	Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast, 2015, 24, S26-S35.	0.9	735
25	Current state of biomarkers in ovarian cancer prognosis. Future Oncology, 2015, 11, 3187-3195.	1.1	45
26	Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells. Molecular Oncology, 2015, 9, 2054-2062.	2.1	85
27	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Annals of Oncology, 2015, 26, 259-271.	0.6	2,122
28	Anatomie pathologique des cancers du sein en phase précoce. , 2016, , 35-48.		0
29	Usefulness of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in hormone-receptor-negative breast cancer. OncoTargets and Therapy, 2016, Volume 9, 4653-4660.	1.0	38
30	The Pretreatment Neutrophil/Lymphocyte Ratio Is Associated with All-Cause Mortality in Black and White Patients with Non-metastatic Breast Cancer. Frontiers in Oncology, 2016, 6, 81.	1.3	13
31	Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study. PLoS Medicine, 2016, 13, e1002194.	3.9	473
32	Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. Journal of Breast Cancer, 2016, 19, 385.	0.8	2
33	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	1.6	143
34	An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers. Breast Cancer Research, 2016, 18, 121.	2.2	89
35	Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nature Communications, 2016, 7, 12258.	5.8	76
36	STAT1â€associated intratumoural T_H1 immunity predicts chemotherapy resistance in highâ€grade serous ovarian cancer. Journal of Pathology: Clinical Research, 2016, 2, 259-270.	1.3	42
37	Prognostic factors of early breast cancer. Medicina ClÃnica (English Edition), 2016, 146, 167-171.	0.1	1

#	Article	IF	Citations
38	The immune system and hormone-receptor positive breast cancer: Is it really a dead end?. Cancer Treatment Reviews, 2016, 46, 9-19.	3.4	84
39	Association of Notch pathway down-regulation with Triple Negative/Basal-like breast carcinomas and high tumor-infiltrating FOXP3 + Tregs. Experimental and Molecular Pathology, 2016, 100, 460-468.	0.9	15
40	Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors. Immunotherapy, 2016, 8, 583-600.	1.0	71
41	Basic Rules of T Cell Migration. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 1-19.	0.1	3
42	Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors. Resistance To Targeted Anti-cancer Therapeutics, 2016, , 179-193.	0.1	0
43	The genomic landscape of breast cancer and its interaction with host immunity. Breast, 2016, 29, 241-250.	0.9	194
44	Tumor-associated macrophages: unwitting accomplices in breast cancer malignancy. Npj Breast Cancer, 2016, 2, .	2.3	356
45	Biopsy variability of lymphocytic infiltration in breast cancer subtypes and the ImmunoSkew score. Scientific Reports, 2016, 6, 36231.	1.6	27
46	Evaluation of HER2 by Automated FISH and IHC in Gastric Carcinoma Biopsies. International Journal of Biological Markers, 2016, 31, 38-43.	0.7	4
47	Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting. Clinical Medicine Insights: Oncology, 2016, 10s1, CMO.S34540.	0.6	121
48	Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 8272-8277.	3.3	56
49	Similar lymphocytic infiltration pattern in primary breast cancer and their corresponding distant metastases. OncoImmunology, 2016, 5, e1153208.	2.1	36
50	Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Research, 2016, 18, 21.	2.2	66
52	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241.	12.5	679
53	Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunology Research, 2016, 4, 41-48.	1.6	25
54	Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nature Reviews Clinical Oncology, 2016, 13, 566-579.	12.5	38
55	Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer. Current Breast Cancer Reports, 2016, 8, 1-13.	0.5	8
56	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. Nature Reviews Clinical Oncology, 2016, 13, 487-503.	12.5	43

#	Article	IF	Citations
57	Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group. Annals of Surgical Oncology, 2016, 23, 2242-2248.	0.7	85
58	Eavesdropping on altered cell-to-cell signaling in cancer by secretome profiling. Molecular and Cellular Oncology, 2016, 3, e1029061.	0.3	6
59	Tumor microenvironment in invasive lobular carcinoma: possible therapeutic targets. Breast Cancer Research and Treatment, 2016, 155, 65-75.	1.1	30
60	Computational pathology: Exploring the spatial dimension of tumor ecology. Cancer Letters, 2016, 380, 296-303.	3.2	53
61	Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. Clinical Breast Cancer, 2016, 16, 51-58.	1.1	71
62	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer, 2017, 24, 3-15.	1.3	165
64	Breast Cancer Immunology and Immunotherapy. International Review of Cell and Molecular Biology, 2017, 331, 1-53.	1.6	47
65	Immunoprofiling as a predictor of patient's response to cancer therapy—promises and challenges. Current Opinion in Immunology, 2017, 45, 60-72.	2.4	39
66	In situ localization of tumor cells associated with the epithelial-mesenchymal transition marker Snail and the prognostic impact of lymphocytes in the tumor microenvironment in invasive ductal breast cancer. Experimental and Molecular Pathology, 2017, 102, 268-275.	0.9	8
67	The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy. Endocrine-Related Cancer, 2017, 24, R123-R144.	1.6	64
68	Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. Cancer Immunology Research, 2017, 5, 330-344.	1.6	28
69	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. Cancer Immunology Research, 2017, 5, 292-299.	1.6	56
70	Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. Breast Cancer Research and Treatment, 2017, 162, 479-488.	1.1	14
71	CD8, FoxP3, and CD45RO+ Lymphocytic Infiltrates in Type I and Type II Endometrial Cancers in African American and European American Females. International Journal of Gynecological Pathology, 2017, 36, 540-549.	0.9	5
72	Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase IIα in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy. Chemotherapy, 2017, 62, 246-255.	0.8	12
73	PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages. American Journal of Surgical Pathology, 2017, 41, 334-342.	2.1	143
74	Relationship of the Breast Ductal Carcinoma *In Situ* Immune Microenvironment with Clinicopathological and Genetic Features. Clinical Cancer Research, 2017, 23, 5210-5217.	3.2	61
75	Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Annals of Oncology, 2017, 28, 1832-1835.	0.6	36

#	ARTICLE	IF	CITATIONS
76	Advancing Immunotherapy in Metastatic Breast Cancer. Current Treatment Options in Oncology, 2017, 18, 35.	1.3	13
77	Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 153-164.	0.4	59
78	Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene, 2017, 36, 4457-4468.	2.6	204
79	Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer. Journal of Clinical Pathology, 2017, 70, 860-867.	1.0	47
80	Connecting the Metabolic and Immune Responses to Cancer. Trends in Molecular Medicine, 2017, 23, 451-464.	3.5	55
81	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology, 2017, 49, 141-155.	0.3	112
82	Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer. OncoImmunology, 2017, 6, e1257452.	2.1	169
83	The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Human Pathology, 2017, 69, 110-117.	1.1	81
84	How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. ESMO Open, 2017, 2, e000208.	2.0	47
85	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 527-537.	3.3	59
86	Neoadjuvant Interferons: Critical for Effective PD-1–Based Immunotherapy in TNBC. Cancer Immunology Research, 2017, 5, 871-884.	1.6	63
87	Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer. Medical Molecular Morphology, 2017, 50, 185-194.	0.4	31
88	Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. Breast, 2017, 35, 142-150.	0.9	87
89	PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. Journal of the American Academy of Dermatology, 2017, 77, 534-542.	0.6	36
90	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer. JAMA Oncology, 2017, 3, e172085.	3.4	37
91	Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. ESMO Open, 2017, 2, e000150.	2.0	105
92	The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis. OncoImmunology, 2017, 6, e1356148.	2.1	247
93	Age, estrogen, and immune response in breast adenocarcinoma and adjacent normal tissue. OncoImmunology, 2017, 6, e1356142.	2.1	34

#	Article	IF	Citations
94	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Current Oncology Reports, 2017, 19, 64.	1.8	106
95	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
96	Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open, 2017, 2, e000255.	2.0	118
97	Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients. Medicine (United States), 2017, 96, e8101.	0.4	39
98	Predictive and prognostic significance of CD8+ tumor-infiltrating lymphocytes in patients with luminal B/HER 2 negative breast cancer treated with neoadjuvant chemotherapy. Oncology Letters, 2017, 14, 337-344.	0.8	33
99	Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. , 2017, 5, 39.		56
100	CD44 induces FOXP3 expression and is related with favorable outcome in breast carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 81-90.	1.4	4
101	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. Cancer Management and Research, 2017, Volume 9, 741-750.	0.9	19
102	Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study. International Journal of Molecular Sciences, 2017, 18, 1936.	1.8	19
103	Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer. Frontiers in Immunology, 2017, 8, 1412.	2.2	80
104	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Frontiers in Oncology, 2017, 7, 156.	1.3	87
105	Predictive and prognostic impact of tumour-infiltrating lymphocytes in triple-negative breast cancer treated with neoadjuvant chemotherapy. Ecancermedicalscience, 2017, 11, 759.	0.6	21
106	Tumor Heterogeneity. , 2017, , 37-55.		7
107	Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 237-252.	0.7	109
108	Tumor-infiltrating lymphocytes and ductal carcinoma in situ of the breast: friends or foes?. Modern Pathology, 2018, 31, 1012-1025.	2.9	25
109	Associations between genomic stratification of breast cancer and centrally reviewed tumour pathology in the METABRIC cohort. Npj Breast Cancer, 2018, 4, 5.	2.3	32
110	Intracystic papillary carcinoma of the breast: Experience of a major Chinese cancer center. Pathology Research and Practice, 2018, 214, 579-585.	1.0	8
111	Immune Infiltration in Invasive Lobular Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 768-776.	3.0	76

#	Article	IF	Citations
112	Density and location of <scp>CD</scp>3⁺ and <scp>CD</scp>8⁺ tumor‐infiltrating lymphocytes correlate with prognosis of oral squamous cell carcinoma. Journal of Oral Pathology and Medicine, 2018, 47, 359-367.	1.4	41
113	Atezolizumab for the treatment of breast cancer. Expert Opinion on Biological Therapy, 2018, 18, 595-603.	1.4	17
114	Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Management, 2018, 7, BMT05.	0.2	4
116	Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell, 2018, 33, 463-479.e10.	7.7	1,074
117	Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Annals of Surgical Oncology, 2018, 25, 937-946.	0.7	37
118	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. Breast Care, 2018, 13, 16-21.	0.8	135
119	Immune Checkpoint Blockade for Breast Cancer. Cancer Treatment and Research, 2018, 173, 155-165.	0.2	69
120	Medical management of brain metastases and leptomeningeal disease in patients with breast carcinoma. Future Oncology, 2018, 14, 391-407.	1.1	22
121	Crosstalk between cancer and the neuro-immune system. Journal of Neuroimmunology, 2018, 315, 15-23.	1.1	48
122	Enhancement of mammary tumour growth by IGFBP-3 involves impaired T cell accumulation. Endocrine-Related Cancer, 2018, 25, 111-122.	1.6	14
123	Checkpoint inhibitors in breast cancer â€" Current status. Cancer Treatment Reviews, 2018, 63, 122-134.	3.4	112
124	The prognostic value of regulatory T cells infiltration in HER2-enriched breast cancer microenvironment. International Reviews of Immunology, 2018, 37, 144-150.	1.5	11
125	Immunotherapy for Other Malignancies. , 2018, , 125-142.		0
126	A New Paradigm for Tissue Diagnostics: Tools and Techniques to Standardize Tissue Collection, Transport, and Fixation. Current Pathobiology Reports, 2018, 6, 135-143.	1.6	10
127	A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy. Seminars in Oncology, 2018, 45, 170-175.	0.8	17
128	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
129	Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Modern Pathology, 2018, 31, 288-298.	2.9	38
130	Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists. Acta OncolÃ³gica, 2018, 57, 90-94.	0.8	35

#	Article	IF	Citations
131	CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy. , 2018, , 23-39.		7
132	Immunomodulatory effects of a bioactive fraction of Strobilanthes crispus in NMU-induced rat mammary tumor model. Journal of Ethnopharmacology, 2018, 213, 31-37.	2.0	16
133	Relevance of Spatial Heterogeneity of Immune Infiltration for Predicting Risk of Recurrence After Endocrine Therapy of ER+ Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 166-175.	3.0	122
134	Estrogen Regulation of T-Cell Function and Its Impact on the Tumor Microenvironment. , 2018, 2, 81-91.	0.8	9
135	Prognostic role of derived neutrophil-to-lymphocyte ratio in surgical triple-negative breast cancer. Cancer Management and Research, 2018, Volume 10, 4891-4898.	0.9	22
136	The Effect of Immunology on Surgical Outcome: an Observational Hypothesis. Immunome Research, 2018, 14, .	0.1	0
137	Classification of triple-negative breast cancers based on Immunogenomic profiling. Journal of Experimental and Clinical Cancer Research, 2018, 37, 327.	3.5	329
138	Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Frontiers in Oncology, 2018, 8, 609.	1.3	17
139	Increased derived neutrophil-to-lymphocyte ratio and Breast Imaging-Reporting and Data System classification predict poor survival in patients with non-distant metastatic HER2+ breast cancer treated with neoadjuvant chemotherapy. Cancer Management and Research, 2018, Volume 10, 3841-3847.	0.9	11
140	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy. Cancer Medicine, 2018, 7, 5066-5082.	1.3	12
141	A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy. , 2018, 6, 100.		53
142	Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. ESMO Open, 2018, 3, e000305.	2.0	34
143	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. Cancer Management and Research, 2018, Volume 10, 4333-4347.	0.9	37
144	Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature Communications, 2018, 9, 4297.	5.8	101
145	Prognostic significance of infiltrating immune cell subtypes in invasive ductal carcinoma of the breast. Tumori, 2018, 104, 196-201.	0.6	26
146	Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2‐positive breast cancer. European Journal of Cancer, 2018, 103, 52-60.	1.3	16
147	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, *BRCA1*-like status, tumor-infiltrating immune cells and survival. OncoImmunology, 2018, 7, e1509820.	2.1	80
148	Hot Spot and Whole-Tumor Enumeration of CD8+ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. Clinical Breast Cancer, 2018, 18, 451-458.e1.	1.1	25

#	Article	IF	Citations
149	Reproducibility and predictive value of scoring stromal tumour infiltrating lymphocytes in triple-negative breast cancer: a multi-institutional study. Breast Cancer Research and Treatment, 2018, 171, 1-9.	1.1	37
150	Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecologic Oncology, 2018, 150, 361-369.	0.6	28
151	Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer. Breast Cancer Research and Treatment, 2018, 171, 65-74.	1.1	11
152	IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1. Modern Pathology, 2018, 31, 1513-1522.	2.9	68
153	Resident Breast T Cells: The Troops Are Already There. Trends in Molecular Medicine, 2018, 24, 821-822.	3.5	1
154	Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. Frontiers in Immunology, 2018, 9, 1765.	2.2	70
155	The Expression and Prognostic Impact of Immune Cytolytic Activity-Related Markers in Human Malignancies: A Comprehensive Meta-analysis. Frontiers in Oncology, 2018, 8, 27.	1.3	71
156	The Role of the Estrogen Pathway in the Tumor Microenvironment. International Journal of Molecular Sciences, 2018, 19, 611.	1.8	145
157	Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. Annals of Surgical Oncology, 2018, 25, 2852-2857.	0.7	15
158	Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Research and Treatment, 2018, 171, 21-31.	1.1	32
159	Characterising the adipose-inflammatory microenvironment in male breast cancer. Endocrine-Related Cancer, 2018, 25, 773-781.	1.6	6
160	PD-L1 Expression is Increased in Metastasizing Squamous Cell Carcinomas and Their Metastases. American Journal of Dermatopathology, 2018, 40, 647-654.	0.3	42
161	Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. OncoImmunology, 2018, 7, e1490854.	2.1	200
162	Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Current Oncology Reports, 2018, 20, 76.	1.8	72
163	Notch signaling pathway suppresses CD8+ T cells activity in patients with lung adenocarcinoma. International Immunopharmacology, 2018, 63, 129-136.	1.7	14
164	Macrophages Promote Circulating Tumor Cellâ€"Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. Cancer Research, 2018, 78, 4241-4252.	0.4	36
165	New horizons in breast cancer: the promise of immunotherapy. Clinical and Translational Oncology, 2019, 21, 117-125.	1.2	21
166	A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma. Molecular Cancer Research, 2019, 17, 131-139.	1.5	92

#	Article	IF	Citations
167	Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene, 2019, 38, 390-405.	2.6	149
168	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Research, 2019, 21, 90.	2.2	81
169	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
170	PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences Are Emerging. A Literature Review. Cancers, 2019, 11, 1033.	1.7	160
171	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	1.3	7
172	Tumorâ€Targeted Drug and CpG Delivery System for Phototherapy and Docetaxelâ€Enhanced Immunotherapy with Polarization toward M1â€Type Macrophages on Triple Negative Breast Cancers. Advanced Materials, 2019, 31, e1904997.	11.1	238
173	Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis. Frontiers in Oncology, 2019, 9, 985.	1.3	16
174	Inhibition of Stat3 Signaling Pathway by Natural Product Pectolinarigenin Attenuates Breast Cancer Metastasis. Frontiers in Pharmacology, 2019, 10, 1195.	1.6	28
175	Immune cell infiltration characteristics and related core genes in lupus nephritis: results from bioinformatic analysis. BMC Immunology, 2019, 20, 37.	0.9	64
176	The Tumor Microenvironment as a Regulator of Endocrine Resistance in Breast Cancer. Frontiers in Endocrinology, 2019, 10, 547.	1.5	26
177	Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy. OncoImmunology, 2019, 8, e1648171.	2.1	31
178	Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. Frontiers in Immunology, 2019, 10, 1939.	2.2	38
179	Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC. Npj Precision Oncology, 2019, 3, 21.	2.3	23
180	Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 3105-3114.	1.2	63
181	Spontaneous regression of occult breast cancer with axillary lymph node metastasis: A case report. International Journal of Surgery Case Reports, 2019, 63, 75-79.	0.2	8
182	Intratumoral, rather than stromal, CD8+ T cells could be a potential negative prognostic marker in invasive breast cancer patients. Translational Oncology, 2019, 12, 585-595.	1.7	36
183	Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches. Breast Cancer: Targets and Therapy, 2019, Volume 11, 53-69.	1.0	63
184	Comparative study of the PD-L1 expression and CD8+ tumor-infiltrating lymphocyte between surgically resected and matched re-biopsy specimens in recurrent non-small cell lung cancer . Therapeutics and Clinical Risk Management, 2019, Volume 15, 605-612.	0.9	2

#	ARTICLE	IF	CITATIONS
185	<p>Prognostic significance of systemic immune-inflammation index in triple-negative breast cancer</p>. Cancer Management and Research, 2019, Volume 11, 4471-4480.	0.9	25
186	<p>Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients</p>. Cancer Management and Research, 2019, Volume 11, 3153-3162.	0.9	24
187	Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy. Cancers, 2019, 11, 714.	1.7	79
188	Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Scientific Reports, 2019, 9, 8572.	1.6	36
189	The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 13-23.	1.4	27
190	T-bet+ lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer. Breast Cancer Research and Treatment, 2019, 176, 569-577.	1.1	18
191	Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1. Breast Disease, 2019, 38, 57-65.	0.4	1
192	Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Communications, 2019, 39, 1-9.	3.7	40
193	CD155 expression and its prognostic value in postoperative patients with breast cancer. Biomedicine and Pharmacotherapy, 2019, 115, 108884.	2.5	34
194	Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology. Frontiers in Immunology, 2019, 10, 348.	2.2	89
195	A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis. Anticancer Research, 2019, 39, 1217-1232.	0.5	21
196	Novel tumor-infiltrating lymphocytes ultrasonography score based on ultrasonic tissue findings predicts tumor-infiltrating lymphocytes in breast cancer. Breast Cancer, 2019, 26, 573-580.	1.3	12
197	BET Inhibition Modifies Melanoma Infiltrating T Cells and Enhances Response to PD-L1 Blockade. Journal of Investigative Dermatology, 2019, 139, 1612-1615.	0.3	17
198	The scope of viral causation of human cancers: interpreting virus density from an evolutionary perspective. Philosophical Transactions of the Royal Society B: Biological Sciences, 2019, 374, 20180304.	1.8	4
199	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. Future Oncology, 2019, 15, 1823-1843.	1.1	14
200	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
201	Effect of Radiotherapy After Breast-Conserving Surgery Depending on the Presence of Tumor-Infiltrating Lymphocytes: A Long-Term Follow-Up of the SweBCG91RT Randomized Trial. Journal of Clinical Oncology, 2019, 37, 1179-1187.	0.8	41
202	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52

#	ARTICLE	IF	CITATIONS
203	Multiplexed (18-Plex) Measurement of Signaling Targets and Cytotoxic T Cells in Trastuzumab-Treated Patients using Imaging Mass Cytometry. Clinical Cancer Research, 2019, 25, 3054-3062.	3.2	42
204	Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltrationÂin triple-negative breast cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 85.	3.5	13
205	Infiltration of CD8 + T cells into tumor cell clusters in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3678-3687.	3.3	108
206	Systemic immune-inflammation index and ultrasonographic classification of breast imaging-reporting and data system predict outcomes of triple-negative breast cancer. Cancer Management and Research, 2019, Volume 11, 813-819.	0.9	14
207	Importance of CD45RO+ tumor-infiltrating lymphocytes in post-operative survival of breast cancer patients. Cellular Oncology (Dordrecht), 2019, 42, 343-356.	2.1	23
208	Interaction of Breast Cancer and Insulin Resistance on PD1 and TIM3 Expression in Peripheral Blood CD8 T Cells. Pathology and Oncology Research, 2019, 25, 1233-1243.	0.9	28
209	Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1977-1985.	1.1	57
210	Utilizing gene expression profiles to characterize tumor infiltrating lymphocytes in cancers. Annals of Translational Medicine, 2019, 7, S289-S289.	0.7	2
211	An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment. Nature Communications, 2019, 10, 5499.	5.8	132
212	Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer. Medicine (United States), 2019, 98, e17262.	0.4	3
213	Long intergenic noncoding RNA 299 methylation in peripheral blood is a biomarker for triple-negative breast cancer. Epigenomics, 2019, 11, 81-93.	1.0	32
214	High Density of Intratumor CD45RO+ Memory Tumor-Infiltrating Lymphocytes Predicts Favorable Prognosis in Patients With Oral Squamous Cell Carcinoma. Journal of Oral and Maxillofacial Surgery, 2019, 77, 536-545.	0.5	16
215	Contrasting effects of IGF binding protein-3 expression in mammary tumor cells and the tumor microenvironment. Experimental Cell Research, 2019, 374, 38-45.	1.2	5
216	Recent advances in breast cancer research impacting clinical diagnostic practice. Journal of Pathology, 2019, 247, 552-562.	2.1	24
217	Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer. Biomaterials, 2019, 195, 86-99.	5.7	79
218	Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. Cancer Treatment Reviews, 2019, 72, 7-14.	3.4	25
219	Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial. International Journal of Cancer, 2020, 146, 262-271.	2.3	27
220	Serum levels of inflammation‐related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. International Journal of Cancer, 2020, 146, 223-235.	2.3	13

#	Article	IF	Citations
221	Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy. Clinical Cancer Research, 2020, 26, 738-745.	3.2	31
222	Usefulness of imaging findings in predicting tumor-infiltrating lymphocytes in patients with breast cancer. European Radiology, 2020, 30, 2049-2057.	2.3	25
223	Tumor Infiltrating Lymphocytes and CD8+â€‰T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. Head and Neck Pathology, 2020, 14, 689-700.	1.3	19
224	Gene Expression Signatures of BRCAness and Tumor Inflammation Define Subgroups of Early-Stage Hormone Receptorâ€"Positive Breast Cancer Patients. Clinical Cancer Research, 2020, 26, 6523-6534.	3.2	16
225	Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA. Oncology, 2020, 98, 817-826.	0.9	4
226	CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 6968.	1.8	118
227	Oestrogen and zoledronic acid driven changes to the bone and immune environments: Potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 2020, 25, 100317.	1.0	18
228	Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. Pathology and Oncology Research, 2020, 26, 2733-2745.	0.9	14
229	Prognostic implications of the expression levels of different immunoglobulin heavy chain-encoding RNAs in early breast cancer. Npj Breast Cancer, 2020, 6, 28.	2.3	25
230	<p>Biomolecular Factors Represented by Bcl-2, p53, and Tumor-Infiltrating Lymphocytes Predict Response for Adjuvant Anthracycline Chemotherapy in Patients with Early Triple-Negative Breast Cancer</p>. Cancer Management and Research, 2020, Volume 12, 11965-11971.	0.9	7
231	Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling. Frontiers in Oncology, 2020, 10, 580029.	1.3	9
232	Characterizing heterogeneity of nonâ€small cell lung tumour microenvironment to identify signature prognostic genes. Journal of Cellular and Molecular Medicine, 2020, 24, 14608-14618.	1.6	10
233	PELICAN-IPC 2015-016/Oncodistinct-003: A Prospective, Multicenter, Open-Label, Randomized, Non-Comparative, Phase II Study of Pembrolizumab in Combination With Neo Adjuvant EC-Paclitaxel Regimen in HER2-Negative Inflammatory Breast Cancer. Frontiers in Oncology, 2020, 10, 575978.	1.3	7
234	Breast Cancer Heterogeneity and Response to Novel Therapeutics. Cancers, 2020, 12, 3271.	1.7	40
235	Frequency of CD4+ regulatory T cells, CD8+ T cells, and human papilloma virus infection in Egyptian Women with breast cancer. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842096682.	1.0	9
236	Adoptive Cell Therapy in Breast Cancer: A Current Perspective of Next-Generation Medicine. Frontiers in Oncology, 2020, 10, 605633.	1.3	25
237	Obesity-Associated Myeloid-Derived Suppressor Cells Promote Apoptosis of Tumor-Infiltrating CD8 T Cells and Immunotherapy Resistance in Breast Cancer. Frontiers in Immunology, 2020, 11, 590794.	2.2	45
238	A comparison of complete pathologic response rates following neoadjuvant chemotherapy among South African breast cancer patients with and without concurrent HIV infection. Breast Cancer Research and Treatment, 2020, 184, 861-872.	1.1	8

#	Article	IF	Citations
239	Breast and Gut Microbiota Action Mechanisms in Breast Cancer Pathogenesis and Treatment. Cancers, 2020, 12, 2465.	1.7	90
240	An IL6â€"Adenosine Positive Feedback Loop between CD73+ Î³ÎTregs and CAFs Promotes Tumor Progression in Human Breast Cancer. Cancer Immunology Research, 2020, 8, 1273-1286.	1.6	32
241	The Role of the Tumor Microenvironment in Developing Successful Therapeutic and Secondary Prophylactic Breast Cancer Vaccines. Vaccines, 2020, 8, 529.	2.1	9
242	Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naÃ¯ve prostate cancer. Prostate, 2020, 80, 1353-1364.	1.2	4
243	Quantitative multiplex immunofluorescence analysis identifies infiltrating PD1+CD8+ and CD8+ T cells as predictive of response to neoadjuvant chemotherapy in breast cancer. Thoracic Cancer, 2020, 11, 2941-2954.	0.8	13
244	TILs Immunophenotype in Breast Cancer Predicts Local Failure and Overall Survival: Analysis in a Large Radiotherapy Trial with Long-Term Follow-Up. Cancers, 2020, 12, 2365.	1.7	18
245	Molecular and Cellular Factors Associated with Racial Disparity in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 5936.	1.8	13
246	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilmsâ€™ tumor. Tumor Biology, 2020, 42, 101042832097597.	0.8	19
247	The Tumor Microenvironment as a Driving Force of Breast Cancer Stem Cell Plasticity. Cancers, 2020, 12, 3863.	1.7	12
248	Increased Stromal Infiltrating Lymphocytes Are Associated with the Risk of Disease Progression in Mesenchymal Circulating Tumor Cell-Positive Primary Breast Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 9460.	1.8	7
249	Prognostic Interactions between FAP+ Fibroblasts and CD8a+ T Cells in Colon Cancer. Cancers, 2020, 12, 3238.	1.7	13
250	An immune cell infiltration-based immune score model predicts prognosis and chemotherapy effects in breast cancer. Theranostics, 2020, 10, 11938-11949.	4.6	85
251	Tumor-Infiltrating CD8 T Cells Predict Clinical Breast Cancer Outcomes in Young Women. Cancers, 2020, 12, 1076.	1.7	31
252	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. Journal of Ovarian Research, 2020, 13, 59.	1.3	13
253	Changes and prognostic values of tumor-infiltrating lymphocyte subsets after primary systemic therapy in breast cancer. PLoS ONE, 2020, 15, e0233037.	1.1	17
254	How are missing data in covariates handled in observational time-to-event studies in oncology? A systematic review. BMC Medical Research Methodology, 2020, 20, 134.	1.4	26
255	Tumor-infiltrating lymphocytes are associated with poor prognosis in invasive lobular breast carcinoma. Modern Pathology, 2020, 33, 2198-2207.	2.9	21
256	Association of TILs with clinical parameters, Recurrence ScoreÂ® results, and prognosis in patients with early HER2-negative breast cancer (BC)â€"a translational analysis of the prospective WSG PlanB trial. Breast Cancer Research, 2020, 22, 47.	2.2	17

#	ARTICLE	IF	CITATIONS
257	Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women. Breast Cancer Research, 2020, 22, 62.	2.2	24
258	Neuroimmunoendocrine Interactions in Tumorigenesis and Breast Cancer. , 2020, , .		1
259	Immunoscore: a novel prognostic tool. Association with clinical outcome, response to treatment and survival in several malignancies. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 432-443.	2.7	22
260	Immune and Stroma Related Genes in Breast Cancer: A Comprehensive Analysis of Tumor Microenvironment Based on the Cancer Genome Atlas (TCGA) Database. Frontiers in Medicine, 2020, 7, 64.	1.2	53
261	Development and verification of a personalized immune prognostic feature in breast cancer. Experimental Biology and Medicine, 2020, 245, 1242-1253.	1.1	2
262	Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma. Frontiers in Oncology, 2020, 10, 950.	1.3	15
263	Akt Inhibition Is Associated With Favorable Immune Profile Changes Within the Tumor Microenvironment of Hormone Receptor Positive, HER2 Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 968.	1.3	15
264	Secreted breast tumor interstitial fluid microRNAs and their target genes are associated with triple-negative breast cancer, tumor grade, and immune infiltration. Breast Cancer Research, 2020, 22, 73.	2.2	29
265	SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncology, 2020, 16, 1801-1813.	1.1	8
266	Levels of different subtypes of tumour-infiltrating lymphocytes correlate with each other, with matched circulating lymphocytes, and with survival in breast cancer. Breast Cancer Research and Treatment, 2020, 183, 49-59.	1.1	10
267	Neoantigen-based immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Cancer Letters, 2020, 490, 12-19.	3.2	10
268	Tumor-infiltrating lymphocytes (TILs) in ER+/HER2â˜’ breast cancer. Breast Cancer Research and Treatment, 2020, 183, 347-354.	1.1	59
269	Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage Iâ€"III patients treated with standard therapy. European Journal of Cancer, 2020, 136, 7-15.	1.3	32
270	Role of LATS1/2 in Prognosis of Advanced Gastric Cancer and Its Relationship With the Tumor Immune Microenvironment. Frontiers in Oncology, 2020, 10, 1406.	1.3	5
271	High Systemic Immune-Inflammation Index Predicts Poor Survival in Patients with Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer Receiving Adjuvant Trastuzumab . Cancer Management and Research, 2020, Volume 12, 475-484.	0.9	14
272	Imaging mass cytometry and multiplatform genomics define the phenogenomic landscape of breast cancer. Nature Cancer, 2020, 1, 163-175.	5.7	209
273	Treatment from within: Ductal Carcinoma as an Opportunity to Harness the Immune System. Current Breast Cancer Reports, 2020, 12, 82-89.	0.5	0
274	Tissue-resident memory T cells in breast cancer control and immunotherapy responses. Nature Reviews Clinical Oncology, 2020, 17, 341-348.	12.5	159

#	ARTICLE	IF	CITATIONS
275	Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. Acta Oncolᗄgica, 2020, 59, 652-659.	0.8	28
276	Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study. World Journal of Surgical Oncology, 2020, 18, 11.	0.8	19
277	Oncolytic Herpes Simplex Virus Encoding IL12 Controls Triple-Negative Breast Cancer Growth and Metastasis. Frontiers in Oncology, 2020, 10, 384.	1.3	45
278	Prognostic impact of a tumor-infiltrating lymphocyte subtype in triple negative cancer of the breast. Breast Cancer, 2020, 27, 880-892.	1.3	20
279	Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer. Clinical Immunology, 2020, 215, 108412.	1.4	17
280	microRNAs in the Antitumor Immune Response and in Bone Metastasis of Breast Cancer: From Biological Mechanisms to Therapeutics. International Journal of Molecular Sciences, 2020, 21, 2805.	1.8	17
281	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. Chinese Medical Journal, 2020, 133, 853-862.	0.9	21
282	Prognosis of PD-L1 in human breast cancer: protocol for a systematic review and meta-analysis. Systematic Reviews, 2020, 9, 66.	2.5	16
283	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. Cancer Immunology, Immunotherapy, 2020, 69, 1549-1564.	2.0	19
284	Combination Immunotherapy with Cytotoxic T-Lymphocyteâ€"Associated Antigen-4 and Programmed Death Protein-1 Inhibitors Prevents Postoperative Breast Tumor Recurrence and Metastasis. Molecular Cancer Therapeutics, 2020, 19, 802-811.	1.9	18
285	The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas. Pathobiology, 2020, 87, 125-142.	1.9	49
286	Association Between FOXP3/CD8 Lymphocyte Ratios and Tumor Infiltrating Lymphocyte Levels in Different Breast Cancer Subtypes. Anticancer Research, 2020, 40, 2141-2150.	0.5	11
287	miR-216a Acts as a Negative Regulator of Breast Cancer by Modulating Stemness Properties and Tumor Microenvironment. International Journal of Molecular Sciences, 2020, 21, 2313.	1.8	13
288	T-cell-based breast cancer immunotherapy. Seminars in Cancer Biology, 2021, 72, 90-101.	4.3	21
289	Immunotherapeutic strategies in breast cancer: A clinical update. Journal of Surgical Oncology, 2021, 123, 710-717.	0.8	4
290	Immune Infiltrate in the Primary Tumor Predicts Effect of Adjuvant Radiotherapy in Breast Cancer; Results from the Randomized SweBCG91RT Trial. Clinical Cancer Research, 2021, 27, 749-758.	3.2	10
291	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 202-212.	3.2	50
292	The prognostic significance of interferon-stimulated gene 15 (ISG15) in invasive breast cancer. Breast Cancer Research and Treatment, 2021, 185, 293-305.	1.1	26

#	ARTICLE	IF	CITATIONS
293	Molecular Heterogeneity and Evolution in Breast Cancer. Annual Review of Cancer Biology, 2021, 5, 79-94.	2.3	14
294	Overexpression of B7-H4 is associated with infiltrating immune cells and poor prognosis in metastatic colorectal cancer. International Immunopharmacology, 2021, 90, 107144.	1.7	13
295	Efficacy of cancer vaccines in selected gynaecological breast and ovarianÂcancers: A 20-year systematic review and meta-analysis. European Journal of Cancer, 2021, 142, 63-82.	1.3	19
296	Immunotherapy for early breast cancer: too soon, too superficial, or just right?. Annals of Oncology, 2021, 32, 323-336.	0.6	79
297	The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Seminars in Cancer Biology, 2021, 72, 76-89.	4.3	87
298	ACE2 Is a Prognostic Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma: Implication for COVID-19. Journal of Oncology, 2021, 2021, 1-15.	0.6	11
299	Breast Tumor Microenvironment in Black Women: A Distinct Signature of CD8+ T-Cell Exhaustion. Journal of the National Cancer Institute, 2021, 113, 1036-1043.	3.0	50
300	Tumor mutation burden in connection with immune-related survival in uterine corpus endometrial carcinoma. Cancer Cell International, 2021, 21, 80.	1.8	14
301	A High-Dimensional Window into the Micro-Environment of Triple Negative Breast Cancer. Cancers, 2021, 13, 316.	1.7	16
302	Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells, 2021, 10, 223.	1.8	115
304	Molecular analyses of triple-negative breast cancer in the young and elderly. Breast Cancer Research, 2021, 23, 20.	2.2	23
305	Atezolizumab and <i>nab</i>-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study. Journal of the National Cancer Institute, 2021, 113, 1005-1016.	3.0	171
306	CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. Nature Communications, 2021, 12, 769.	5.8	42
307	Protein-based immune profiles of basal-like vs. luminal breast cancers. Laboratory Investigation, 2021, 101, 785-793.	1.7	9
308	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects. Frontiers in Oncology, 2020, 10, 600573.	1.3	100
309	Genetically Predicted C-Reactive Protein Associated With Postmenopausal Breast Cancer Risk: Interrelation With Estrogen and Cancer Molecular Subtypes Using Mendelian Randomization. Frontiers in Oncology, 2020, 10, 630994.	1.3	3
310	Prognostic Value of Natural Killer Cells Besides Tumor-Infiltrating Lymphocytes in Breast Cancer Tissues. Clinical Breast Cancer, 2021, 21, e738-e747.	1.1	16
311	Correlation of immune infiltration with clinical outcomes in breast cancer patients: The 25â€gene prognostic signatures model. Cancer Medicine, 2021, 10, 2112-2124.	1.3	3

#	Article	IF	Citations
312	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19â€"IL2 cures poorly immunogenic tumors when combined with radiotherapy. , 2021, 9, e001764.		23
313	An immuneâ€related sevenâ€lncRNA signature for head and neck squamous cell carcinoma. Cancer Medicine, 2021, 10, 2268-2285.	1.3	14
314	Tumor-infiltrating B cells and T cells correlate with postoperative prognosis in triple-negative carcinoma of the breast. BMC Cancer, 2021, 21, 286.	1.1	25
315	Clinical Potential of Kinase Inhibitors in Combination with Immune Checkpoint Inhibitors for the Treatment of Solid Tumors. International Journal of Molecular Sciences, 2021, 22, 2608.	1.8	13
316	Classification of pediatric gliomas based on immunological profiling: Implications for immunotherapy strategies. Molecular Therapy - Oncolytics, 2021, 20, 34-47.	2.0	18
317	Crosstalk between microRNA expression and DNA methylation drives the hormone-dependent phenotype of breast cancer. Genome Medicine, 2021, 13, 72.	3.6	27
319	Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor Models. Cells, 2021, 10, 845.	1.8	4
320	Predicting cell invasion in breast tumor microenvironment from radiological imaging phenotypes. BMC Cancer, 2021, 21, 370.	1.1	17
322	Optimized tumour infiltrating lymphocyte assessment for triple negative breast cancer prognostics. Breast, 2021, 56, 78-87.	0.9	18
323	Prognostic significance of tumor-infiltrating lymphocytes and macrophages in nasopharyngeal carcinoma: a systematic review and meta-analysis. European Archives of Oto-Rhino-Laryngology, 2022, 279, 25-35.	0.8	15
324	The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer. Breast Cancer Research and Treatment, 2021, 187, 635-645.	1.1	3
325	Tumor-Associated Stromal Cellular Density as a Predictor of Recurrence and Mortality in Breast Cancer: Results from Ethnically Diverse Study Populations. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1397-1407.	1.1	7
326	Prognostic Role of Tumorâ€infiltrating Lymphocytes and Tumor Budding in Early Oral Tongue Carcinoma. Laryngoscope, 2021, 131, 2512-2518.	1.1	10
327	Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer. Cancer and Metastasis Reviews, 2021, 40, 519-536.	2.7	56
328	Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence. Histopathology, 2021, 79, 139-159.	1.6	9
329	The Immunology of Hormone Receptor Positive Breast Cancer. Frontiers in Immunology, 2021, 12, 674192.	2.2	68
331	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer. Frontiers in Molecular Biosciences, 2021, 8, 668534.	1.6	14
332	Tumor microenvironment in triple-negative breast cancer: the correlation of tumor-associated macrophages and tumor-infiltrating lymphocytes. Clinical and Translational Oncology, 2021, 23, 2513-2525.	1.2	30

#	ARTICLE	IF	CITATIONS
333	CD8 ⁺ T cell immunity blocks the metastasis of carcinogen-exposed breast cancer. Science Advances, 2021, 7, .	4.7	24
334	An Immunohistochemical Study of Î²-catenin Expression and Immune Cell Population in Metastatic Carcinoma to the Liver. Pathology and Oncology Research, 2021, 27, 1609752.	0.9	2
335	Nodal status in luminal A invasive breast cancer: relationships with cytotoxic CD8â€‰+â€‰and regulatory FOXP3â€‰+â€‰cells tumor-associated infiltrate and other prognostic factors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 871-882.	1.4	0
336	Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer. , 2021, 9, e002036.		4
337	The value of tumor-infiltrating lymphocytes and CD8 expression as a predictor of response to anthracycline-based neoadjuvant chemotherapy in invasive breast carcinoma of no special type. Breast Disease, 2021, 40, S9-S14.	0.4	0
338	Exploring the Potential of Breast Microbiota as Biomarker for Breast Cancer and Therapeutic Response. American Journal of Pathology, 2021, 191, 968-982.	1.9	21
339	Single-Cell Transcriptome Analysis Reveals the M2 Macrophages and Exhausted T Cells and Intratumoral Heterogeneity in Triple-Negative Breast Cancer. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 294-312.	0.9	7
340	GMFG Has Potential to Be a Novel Prognostic Marker and Related to Immune Infiltrates in Breast Cancer. Frontiers in Oncology, 2021, 11, 629633.	1.3	5
341	Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer. Journal of Immunology Research, 2021, 2021, 1-15.	0.9	15
342	Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology. Anti-Cancer Agents in Medicinal Chemistry, 2022, 22, 787-800.	0.9	25
343	Identification of Prognostic miRNAs Associated With Immune Cell Tumor Infiltration Predictive of Clinical Outcomes in Patients With Non-Small Cell Lung Cancer. Frontiers in Oncology, 2021, 11, 705869.	1.3	4
344	Tumor Microenvironment: Key Players in Triple Negative Breast Cancer Immunomodulation. Cancers, 2021, 13, 3357.	1.7	35
345	Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1876, 188587.	3.3	32
346	Comprehensive Analysis of RUNX and TGF-Î² Mediated Regulation of Immune Cell Infiltration in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 730380.	1.8	12
347	Tumor Microenvironment in Breast Cancerâ€"Updates on Therapeutic Implications and Pathologic Assessment. Cancers, 2021, 13, 4233.	1.7	72
348	Anticancer Properties of Strobilanthes crispus: A Review. Processes, 2021, 9, 1370.	1.3	6
349	Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. British Journal of Cancer, 2021, 125, 1388-1398.	2.9	11
351	Best Practices for Spatial Profiling for Breast Cancer Research with the GeoMxÂ® Digital Spatial Profiler. Cancers, 2021, 13, 4456.	1.7	50

#	ARTICLE	IF	CITATIONS
352	Classification of Estrogen Receptor-Positive Breast Cancer Based on Immunogenomic Profiling and Validation at Single-Cell Resolution. Frontiers in Cell and Developmental Biology, 2021, 9, 722841.	1.8	0
353	Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer. Cancers, 2021, 13, 4884.	1.7	11
355	Therapeutic inhibition of USP9x-mediated Notch signaling in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	29
356	Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine, 2021, 71, 103542.	2.7	6
357	Comprehensive Analysis of Pyroptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Breast Cancer. Frontiers in Immunology, 2021, 12, 748221.	2.2	40
358	Immune landscape of inflammatory breast cancer suggests vulnerability to immune checkpoint inhibitors. OncoImmunology, 2021, 10, 1929724.	2.1	22
359	Antitumour immunity regulated by aberrant ERBB family signalling. Nature Reviews Cancer, 2021, 21, 181-197.	12.8	141
360	Efficient gene expression signature for a breast cancer immuno-subtype. PLoS ONE, 2021, 16, e0245215.	1.1	2
361	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. OncoImmunology, 2021, 10, 1924492.	2.1	8
362	The Impact of Estrogen in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1277, 33-52.	0.8	21
363	Notch Signaling and the Breast Cancer Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1287, 183-200.	0.8	24
364	A radiosensitivity gene signature and PD-L1 status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas (TCGA) dataset. Radiotherapy and Oncology, 2017, 124, 403-410.	0.3	31
365	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nature Medicine, 2018, 24, 986-993.	15.2	689
366	Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma. Bioscience Reports, 2020, 40, .	1.1	10
367	Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer. Clinical Science, 2020, 134, 711-726.	1.8	20
371	Systemic Immune-Inflammation Index Is Superior to Neutrophil to Lymphocyte Ratio in Prognostic Assessment of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. BioMed Research International, 2020, 2020, 1-10.	0.9	24
372	Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight, 2019, 4, .	2.3	83
373	Physiologically activated mammary fibroblasts promote postpartum mammary cancer. JCI Insight, 2017, 2, e89206.	2.3	39

#	Article	IF	Citations
374	PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity. Journal of Clinical Investigation, 2018, 128, 2787-2801.	3.9	28
375	Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers. Journal of Clinical Investigation, 2019, 129, 1785-1800.	3.9	266
376	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0152500.	1.1	219
377	Maternal obesity increases offspring's mammary cancer recurrence and impairs tumor immune response. Endocrine-Related Cancer, 2020, 27, 469-482.	1.6	10
378	The overview of modern approaches in treatment of triple negative breast cancer. Issledovaniâ I Praktika V Medicine, 2020, 7, 55-65.	0.1	1
379	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	1.4	99
380	Construction and validation of an immunity-related prognostic signature for breast cancer. Aging, 2020, 12, 21597-21612.	1.4	9
381	Increased gene expression noise in human cancers is correlated with low p53 and immune activities as well as late stage cancer. Oncotarget, 2016, 7, 72011-72020.	0.8	33
382	Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer. Oncotarget, 2017, 8, 15610-15620.	0.8	21
383	Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget, 2017, 8, 57121-57133.	0.8	31
384	Towards tumor immunodiagnostics. Annals of Translational Medicine, 2016, 4, 263-263.	0.7	11
385	The Influence of Host Factors on the Prognosis of Breast Cancer: Stroma and Immune Cell Components as Cancer Biomarkers. Current Cancer Drug Targets, 2015, 15, 652-664.	0.8	33
386	Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	1.3	11
387	The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. Journal of Cancer Research and Therapeutics, 2018, 14, 619.	0.3	5
388	Current Issues and Clinical Evidence in Tumor-Infiltrating Lymphocytes in Breast Cancer. Journal of Pathology and Translational Medicine, 2015, 49, 355-363.	0.4	41
389	Therapeutic strategies to reverse immunosuppressive breast cancer microenvironment. Oncology Discovery, 2016, 4, 1.	0.5	2
390	Sex-Based Differences in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1329, 499-533.	0.8	3
391	RELATIONSHIP OF LYMPHOCYTE SUBPOPULATIONS IN BREAST CANCER PATIENTS WITH TREATMENT RESULTS. , 2021, 20, 25-33.	0.3	3

#	ARTICLE	IF	CITATIONS
392	A Mathematical Model of Breast Tumor Progression Based on Immune Infiltration. Journal of Personalized Medicine, 2021, 11, 1031.	1.1	18
393	MS4A1 as a Potential Independent Prognostic Factor of Breast Cancer Related to Lipid Metabolism and Immune Microenvironment Based on TCGA Database Analysis. Medical Science Monitor, 2022, 27, e934597.	0.5	5
394	Construction and Identification of a Novel 5-Gene Signature for Predicting the Prognosis in Breast Cancer. Frontiers in Medicine, 2021, 8, 669931.	1.2	10
395	Adjuvant Systemic Treatment for Breast Cancer: An Overview. , 2016, , 311-321.		0
396	Molecular Classification of Breast Cancer. , 2016, , 203-219.		2
397	Immunotherapy Approaches to Breast Cancer. Current Breast Cancer Reports, 2017, 9, 227-235.	0.5	0
400	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. IScience, 2021, 24, 103348.	1.9	10
401	The Immune Landscape in Women Cancers. Cancer Treatment and Research, 2020, 180, 215-249.	0.2	3
402	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
403	Immunopathology and Immunotherapy for Breast Cancer. , 2020, , 541-555.		1
404	IMMUNE CHECKPOINT BLOCKADE IN BREAST CANCER THERAPY. International Medical Journal, 2020, , 33-38.	0.1	0
405	Tumor PD-L1 and VEGF Expression, and CD8 T Cell Infiltration Predict Clinical Response to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. Anticancer Research, 2021, 41, 5469-5475.	0.5	4
406	Peritumoral immune infiltrates in primary tumours are not associated with the presence of axillary lymph node metastasis in breast cancer: a retrospective cohort study. PeerJ, 2020, 8, e9779.	0.9	2
407	An immune-related signature that to improve prognosis prediction of breast cancer. American Journal of Cancer Research, 2021, 11, 1267-1285.	1.4	4
408	Immune cytolytic activity is associated with reduced intra-tumoral genetic heterogeneity and with better clinical outcomes in triple negative breast cancer. American Journal of Cancer Research, 2021, 11, 3628-3644.	1.4	3
409	Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis. Breast Cancer Research and Treatment, 2022, 191, 443-450.	1.1	3
410	Novel Insights into the Prognosis and Immunological Value of the SLC35A (Solute Carrier 35A) Family Genes in Human Breast Cancer. Biomedicines, 2021, 9, 1804.	1.4	11
411	Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 774088.	1.3	7

#	ARTICLE	IF	CITATIONS
412	Genomic mutation features identify distinct BRCA-associated mutation characteristics in endometrioid carcinoma and endometrioid ovarian carcinoma. Aging, 2021, 13, 24686-24709.	1.4	4
413	The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance. Cancers, 2021, 13, 6012.	1.7	26
414	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
415	Clinical Progress of PD-1/L1 Inhibitors in Breast Cancer Immunotherapy. Frontiers in Oncology, 2021, 11, 724424.	1.3	12
416	A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors. Science Immunology, 2022, 7, eabi6899.	5.6	36
417	A CD8+ T Cell-Related Genes Expression Signature Predicts Prognosis and the Efficacy of Immunotherapy in Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2022, 27, 53-65.	1.0	5
418	Identifying glycolysis-related LncRNAs for predicting prognosis in breast cancer patients. Cancer Biomarkers, 2022, 34, 393-401.	0.8	3
419	Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma. Annals of Diagnostic Pathology, 2022, 57, 151901.	0.6	6
420	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptorâ€"positive breast cancer. JCI Insight, 2022, 7, .	2.3	17
421	TAMpepK Suppresses Metastasis through the Elimination of M2-Like Tumor-Associated Macrophages in Triple-Negative Breast Cancer. International Journal of Molecular Sciences, 2022, 23, 2157.	1.8	5
422	Correlation between Tumor Microenvironment and Immune Subtypes Based on CD8 T Cells Enhancing Personalized Therapy of Gastric Cancer. Journal of Oncology, 2022, 2022, 1-23.	0.6	2
423	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies. Clinical Epigenetics, 2022, 14, 31.	1.8	18
424	Tumor-associated macrophages (TAMs) modulate response to HER2-targeted agents in a humanized mouse model of breast cancer. Clinical and Translational Oncology, 2022, , 1.	1.2	1
425	Genome-wide identification and analysis of prognostic features in human cancers. Cell Reports, 2022, 38, 110569.	2.9	48
426	Tissue-resident FOLR2+ macrophages associate with CD8+ TÂcell infiltration in human breast cancer. Cell, 2022, 185, 1189-1207.e25.	13.5	166
427	Tumor cell intrinsic and extrinsic features predictÂprognosis in estrogen receptor positive breast cancer. PLoS Computational Biology, 2022, 18, e1009495.	1.5	0
428	A pan-tissue DNA methylation atlas enables in silico decomposition of human tissue methylomes at cell-type resolution. Nature Methods, 2022, 19, 296-306.	9.0	46
429	CD8+ T Cells in SARS-CoV-2 Induced Disease and Cancerâ€"Clinical Perspectives. Frontiers in Immunology, 2022, 13, 864298.	2.2	11

#	ARTICLE	IF	CITATIONS
430	Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews, 2022, 106, 102392.	3.4	11
431	Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial. European Journal of Cancer, 2022, 165, 157-168.	1.3	20
432	Immune response and inflammation in cancer health disparities. Trends in Cancer, 2022, 8, 316-327.	3.8	21
433	Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Breast Cancer: Looking beyond Tumoral PD-L1. Biomedicines, 2021, 9, 1863.	1.4	10
434	Immune landscape of advanced gastric cancer tumor microenvironment identifies immunotherapeutic relevant gene signature. BMC Cancer, 2021, 21, 1324.	1.1	8
435	Assessing PD-L1 Expression Status Using Radiomic Features from Contrast-Enhanced Breast MRI in Breast Cancer Patients: Initial Results. Cancers, 2021, 13, 6273.	1.7	9
436	Identification of a Lipid Metabolism-Associated Gene Signature Predicting Survival in Breast Cancer. International Journal of General Medicine, 2021, Volume 14, 9503-9513.	0.8	8
437	Development and Validation of a Novel Hypoxia-Related Long Noncoding RNA Model With Regard to Prognosis and Immune Features in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 796729.	1.8	8
438	Local Biomarkers Involved in the Interplay between Obesity and Breast Cancer. Cancers, 2021, 13, 6286.	1.7	10
440	Breast cancer microenvironment and obesity: challenges for therapy. Cancer and Metastasis Reviews, 2022, 41, 627-647.	2.7	13
441	Dynamic changes in the tumor microenvironment under the effect of estradiol as a diagnostic tool and target for targeted cancer therapy. Bulletin of Siberian Medicine, 2022, 21, 171-182.	0.1	1
442	The ratio of CD8â€‰+â€‰lymphocytes to tumor-infiltrating suppressive FOXP3â€‰+â€‰effector regulatory T cells is associated with treatment response in invasive breast cancer. Discover Oncology, 2022, 13, 27.	0.8	10
443	Investigating the Prognostic Relevance of Tumor Immune Microenvironment and Immune Gene Assembly in Breast Carcinoma Subtypes. Cancers, 2022, 14, 1942.	1.7	2
444	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. Cancers, 2022, 14, 1999.	1.7	5
445	Breast tumor microenvironment structures are associated with genomic features and clinical outcome. Nature Genetics, 2022, 54, 660-669.	9.4	88
478	Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.. American Journal of Translational Research (discontinued), 2021, 13, 12750-12762.	0.0	0
479	T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis. Frontiers in Immunology, 2022, 13, 760763.	2.2	1
480	Development of an immune-related prognostic biomarker for triple-negative breast cancer. Annals of Medicine, 2022, 54, 1212-1220.	1.5	6

#	ARTICLE	IF	CITATIONS
481	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer. Npj Breast Cancer, 2022, 8, 56.	2.3	3
482	Macrophage density is an adverse prognosticator for ipsilateral recurrence in ductal carcinoma in situ. Breast, 2022, 64, 35-40.	0.9	3
483	The breast cancer immune microenvironment is modified by neoadjuvant chemotherapy. Scientific Reports, 2022, 12, 7981.	1.6	15
484	Immunological profiles of the breast cancer microenvironment represented by tumor-infiltrating lymphocytes and PD-L1 expression. Scientific Reports, 2022, 12, 8098.	1.6	6
485	Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 47-59.	1.8	8
487	Inter‐observer agreement of tumor infiltrating lymphocytes in primary <scp>HER2</scp>‐positive breast cancer and correlation between tissue microarray and full tumor‐sections. Apmis, 2022, 130, 545-550.	0.9	1
488	The immune-based prognostic score for the immunogenomic landscape analysis and application of chemotherapy in breast cancer. Current Bioinformatics, 2022, 17, .	0.7	0
490	Prognostic Significance of Lymphocyte Infiltrate Localization in Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2022, 12, 941.	1.1	3
492	Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor. Japanese Journal of Radiology, 2022, 40, 1307-1315.	1.0	1
493	CISH Expression Is Associated with Metastasis-Free Interval in Triple-Negative Breast Cancer and Refines the Prognostic Value of PDL1 Expression. Cancers, 2022, 14, 3356.	1.7	2
494	De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clinical Cancer Research, 2022, 28, 4995-5003.	3.2	6
495	Immune checkpoint blockade in hormone receptor-positive breast cancer: Resistance mechanisms and future perspectives. Clinical Breast Cancer, 2022, , .	1.1	2
496	Immunology and immunotherapy in breast cancer. Cancer Biology and Medicine, 2022, 19, 609-618.	1.4	10
497	Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer. Human Antibodies, 2022, , 1-20.	0.6	0
498	Immunologic determinants of mammary tumors: PD-L1 and TILS. Revista De Senologia Y Patologia Mamaria, 2022, 35, S60-S66.	0.0	0
499	Immune-Related Biomarkers Improve Performance of Risk Prediction Models for Survival in Patients With Hepatocellular Carcinoma. Frontiers in Oncology, 0, 12, .	1.3	0
500	Exploration and validation of metastasis-associated genes for skin cutaneous melanoma. Scientific Reports, 2022, 12, .	1.6	5
501	Editorial: Advancements in immunology and immunotherapy for breast cancer. Frontiers in Oncology, 0, 12, .	1.3	1

#	ARTICLE	IF	CITATIONS
502	The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively. Journal of Medical Ultrasonics (2001), 2022, 49, 709-717.	0.6	2
503	Strobilanthes crispus elicits anti-tumor immunogenicity in in vitro and in vivo metastatic breast carcinoma. PLoS ONE, 2022, 17, e0271203.	1.1	2
504	The Landscape of Tumor-Infiltrating Immune Cells in Feline Mammary Carcinoma: Pathological and Clinical Implications. Cells, 2022, 11, 2578.	1.8	7
505	CD39 $^+$ tissue-resident memory CD8 $^+$ T cells with a clonal overlap across compartments mediate antitumor immunity in breast cancer. Science Immunology, 2022, 7, .	5.6	23
506	Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers, 2022, 14, 3808.	1.7	2
507	Immune cells markers within local tumor microenvironment are associated with EBV oncoprotein in nasopharyngeal cancer. BMC Cancer, 2022, 22, .	1.1	2
508	Clever-1 positive macrophages in breast cancer. Breast Cancer Research and Treatment, 2022, 195, 237-248.	1.1	2
509	Replenishment of myeloid-derived suppressor cells (MDSCs) overrides CR-mediated protection against tumor growth in a murine model of triple-negative breast cancer. GeroScience, 2022, 44, 2471-2490.	2.1	2
510	Exploration of shared TF-miRNAâ€'mRNA and mRNA-RBP-pseudogene networks in type 2 diabetes mellitus and breast cancer. Frontiers in Immunology, 0, 13, .	2.2	2
511	Haptoglobin genotypes and malaria comorbidity in breast cancer and healthy Nigerian women. Annals of African Medicine, 2022, 21, 231.	0.2	0
512	GRHL2 Expression Functions in Breast Cancer Aggressiveness and Could Serve as Prognostic and Diagnostic Biomarker for Breast Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211095.	0.6	4
513	Multiplex immunohistochemistry and high-throughput image analysis for evaluation of spatial tumor immune cell markers in human breast cancer. Cancer Biomarkers, 2022, 35, 193-206.	0.8	1
514	VISTA is associated with immune infiltration and predicts favorable prognosis in TNBC. Frontiers in Oncology, 0, 12, .	1.3	3
515	Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer. Frontiers in Immunology, 0, 13, .	2.2	5
516	Protein Profiling of Breast Carcinomas Reveals Expression of Immune-Suppressive Factors and Signatures Relevant for Patient Outcome. Cancers, 2022, 14, 4542.	1.7	0
517	Patterns of immune infiltration and survival in endocrine therapy-treated ER-positive breast cancer: A computational study of 1900 patients. Biomedicine and Pharmacotherapy, 2022, 155, 113787.	2.5	7
518	Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study). Oncology Research, 2021, 29, 319-329.	0.6	1
519	The Prognostic Impact of Tumor-Infiltrated Lymphocytes (TILs) in Breast Cancer. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
520	CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome. Brazilian Journal of Otorhinolaryngology, 2022, 88, S133-S142.	0.4	1
521	Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer. Cancers, 2022, 14, 4885.	1.7	5
522	Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. Journal of Translational Medicine, 2022, 20, .	1.8	24
523	Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Frontiers in Oncology, 0, 12, .	1.3	6
524	CD8+ T cell metabolic changes in breast cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2023, 1869, 166565.	1.8	0
525	Unsupervised Analysis Based on DCE-MRI Radiomics Features Revealed Three Novel Breast Cancer Subtypes with Distinct Clinical Outcomes and Biological Characteristics. Cancers, 2022, 14, 5507.	1.7	6
526	Integrative prognostic analysis of tumorâ€"infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. Breast Cancer Research and Treatment, 2023, 197, 287-297.	1.1	4
527	Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nursesâ€™ health study. Breast Cancer Research, 2022, 24, .	2.2	2
528	Association between CD8+ Tumor Infiltrating Lymphocytes and the Clinical Outcome of Patients with Operable Breast Cancer Treated with Adjuvant Dose-Dense Chemotherapyâ€"A 10 Year Follow-Up Report of a Hellenic Cooperative Oncology Group Observational Study. Cancers, 2022, 14, 5635.	1.7	3
529	Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Seminars in Cancer Biology, 2023, 88, 46-66.	4.3	23
530	The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study. Pathogens, 2022, 11, 1421.	1.2	2
531	Screening of the novel immune-suppressive biomarkers of TMED family and whether knockdown of TMED2/3/4/9 inhibits cell migration and invasion in breast cancer. Annals of Translational Medicine, 2022, 10, 1280-1280.	0.7	2
532	Prognostic value of CD8^{+} tumorâ€'infiltrating Tâ€cells in patients with breast cancer: A systematic review and metaâ€'analysis. Oncology Letters, 2022, 25, .	0.8	7
533	The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. Cancer Discovery, 2023, 13, 23-40.	7.7	35
534	Racial/Ethnic Differences Among Tumor-Infiltrating Lymphocytes in Breast Cancer Tumors. Oncologist, 2023, 28, 116-122.	1.9	4
535	Foods may modify responsiveness to cancer immune checkpoint blockers by altering both the gut microbiota and activation of estrogen receptors in immune cells. , 0, 1, .		2
536	A Novel Inflammatory and Nutritional Prognostic Scoring System for Nonpathological Complete Response Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy. Disease Markers, 2022, 2022, 1-29.	0.6	3
537	Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies. Biomedicines, 2023, 11, 238.	1.4	2

#	Article	IF	Citations
538	Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. Diagnostic Pathology, 2023, 18, .	0.9	0
539	Tumor-infiltrating lymphocytes: Prognostic considerations and current trials as adoptive cell therapy. , 2023, , 403-426.		0
540	The Tumor Immune Microenvironment in Cutaneous Squamous Cell Carcinoma Arising in Organ Transplant Recipients. Annals of Dermatology, 2023, 35, 91.	0.3	1
542	Syndecan-1 as an immunogen in Triple-negative breast cancer: regulation tumor-infiltrating lymphocyte in the tumor microenviroment and EMT by TGFb1/Smad pathway. Cancer Cell International, 2023, 23, .	1.8	0
543	Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers, 2023, 15, 767.	1.7	13
544	Association of Enolase-1 with Prognosis and Immune Infiltration in Breast Cancer by Clinical Stage. Journal of Inflammation Research, 0, Volume 16, 493-503.	1.6	0
545	The prognostic value and response to immunotherapy of immunogenic cell death-associated genes in breast cancer. Frontiers in Oncology, 0, 13, .	1.3	2
546	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. Cancers, 2023, 15, 1164.	1.7	4
547	Prognostic and Predictive Biomarkers in Familial Breast Cancer. Cancers, 2023, 15, 1346.	1.7	0
548	Cytotoxic Lymphocyte-Related Gene Signature in Triple-Negative Breast Cancer. Journal of Personalized Medicine, 2023, 13, 457.	1.1	2
549	Identification of STAT5B as a biomarker associated with prognosis and immune infiltration in breast cancer. Medicine (United States), 2023, 102, e32972.	0.4	0
550	Construction and validation of chemoresistance-associated tumor- infiltrating exhausted-like CD8+ T cell signature in breast cancer: cr-TILCD8TSig. Frontiers in Immunology, 0, 14, .	2.2	2
551	Exploring heterogeneity of tumor immune cells and adrenal cells in aldosterone-producing adenomas using single-cell RNA-seq and investigating differences by sex. Heliyon, 2023, 9, e14357.	1.4	2
552	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Frontiers in Immunology, 0, 14, .	2.2	1
553	The prognostic value of tumour-infiltrating lymphocytes, programmed cell death protein-1 and programmed cell death ligand-1 in Stage Iâ€"III triple-negative breast cancer. British Journal of Cancer, 2023, 128, 2044-2053.	2.9	3
554	Cut-off Analysis of HLA-A and HLA-B/C Expression as a Potential Prognosticator of Favorable Survival in Patients With Metastatic Breast Cancer. Anticancer Research, 2023, 43, 1449-1454.	0.5	2
555	ÐÐ¾Ð»ÑŒ Ð¸Ð¼Ð¼ÑƒÐ½Ð½Ð¾Ð³Ð¾ Ð¼Ð¸ÐºÑ€Ð¾Ð¾ÐºÑ€ÑƒÐ¶ÐµÐ½Ð¸Ñ•Ð² Ñ€Ð°Ð·Ð²Ð¸Ñ‚Ð¸Ð¸ Ñ€Ð°ÐºÐ°Ð²Ð¼Ð¾Ð»Ð¾Ñ‡Ð		0
587	Inflammation, Nutrition, and Clinical Outcomes in Breast Cancer Survivors: A Narrative Review. Current Nutrition Reports, 2023, 12, 643-661.	2.1	2

#	ARTICLE	IF	CITATIONS
591	, . Epigenetics and Human Health, 2023, diponectin to Leptin Ratio in Women with Polycystic Ovarian Syndrome.	0.2	0